CoChat

PHASE 1, DOSE-RANGING STUDY OF EMIXUSTAT HYDROCHLORIDE (ACU-4429), A NOVEL VISUAL CYCLE MODULATOR, IN HEALTHY VOLUNTEERS

Kubota, Ryo, Al-Fayoumi, Suliman, Mallikaarjun, Suresh, Patil, Shiva, Bavik, Claes, Chandler, John W. · 2014 · Retina
Cited by 73

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

In Brief Background: Emixustat hydrochloride (formerly ACU-4429) is a nonretinoid compound with a unique mode of action in the retinal pigment epithelium, where it modulates the biosynthesis of visual chromophore through its effect on retinal pigment epithelium-specific 65 kDa protein isomerase. This study provides clinicians with a background for understanding the pharmacokinetics and safety profile of orally administered emixustat. Methods: This randomized, double-masked, placebo-controlled Phase 1b study evaluated the pharmacokinetics, tolerability, and safety of a 14-day course of oral emixustat (5, 10, 20, 30, or 40 mg) or placebo (3:1 ratio) once daily in healthy volunteers. Results: A total of 40 subjects were enrolled (mean age, 38 years; 75% male). Emixustat (n = 30) was rapidly absorbed (median Tmax, 3.0–5 hours) and readily eliminated (mean t1/2, 4.6–7.9 hours), and mean Cmax and AUC0–24 generally increased in proportion to dose. No significant accumulation of emixustat was observed with multiple-dose administration. Ocular adverse events occurred in 67% of the subjects who received emixustat; all were considered mild and resolved after study completion. Systemic adverse events were minimal. Conclusion: Oral emixustat was safe and well tolerated when administered once daily for 14 days with minimal systemic adverse events reported. These data support evaluation of emixustat in subjects with geographic atrophy associated with dry age-related macular degeneration. Emixustat hydrochloride (formerly ACU-4429) is a novel oral drug being studied as a therapy for the treatment of geographic atrophy associated with dry age-related macular degeneration. In this Phase 1b study, oral emixustat (5–40 mg) administered once daily for 14 days was safe and well tolerated in healthy volunteers. Emixustat was rapidly absorbed and readily eliminated, and did not accumulate with repeated-dose administration.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/01.iae.0000434565.80060.f8

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 73

Metadata

Authors
Kubota, R., Al-Fayoumi, S., Mallikaarjun, S., Patil, S., Bavik, C., & Chandler, J. W.
Venue
Retina
Published
2014-03
Volume
34
Issue
3
Pages
603-609
ISSN
0275-004X (ISSN-L)
OpenAlex
W1981544118
Cited by
73
References
7
FWCI
6.02
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PHASE 1, DOSE-RANGING STUDY OF EMIXUSTAT HYDROCHLORIDE (ACU-4429), A NOVEL VISUAL CYCLE MODULATOR, IN HEALTHY VOLUNTEERS. https://app.cochat.ai/papers/10.1097/01.iae.0000434565.80060.f8
The paper
Kubota, R., Al-Fayoumi, S., Mallikaarjun, S., Patil, S., Bavik, C., & Chandler, J. W. (2014). PHASE 1, DOSE-RANGING STUDY OF EMIXUSTAT HYDROCHLORIDE (ACU-4429), A NOVEL VISUAL CYCLE MODULATOR, IN HEALTHY VOLUNTEERS. Retina. https://doi.org/10.1097/01.iae.0000434565.80060.f8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.